Wednesday, August 10, 2022
Home Tags Citius

Tag: citius

@NCI
CoronaVirus

Citius (CTXR) Expands Scientific Advisory Board. Dr. John Laffey, Expert in...

Editor / Curator -
Citius, Biotech Stock Review
2020 Watch List

Adding Citius Pharma (CTXR) $1.29 to the 2021 Biotech Portfolio.

Editor / Curator -
Biotech News

Where is Citius Pharma (CTXR) in the FDA Approval Process?

Editor / Curator -
Citius Pharma
2020 Watch List

Citius Pharma (CTXR) On The Move.

Editor / Curator -
Superbug News - CoronaVirus Watch List

New Report: Citius (CTXR) Trades 13 Million Shares on CoronaVirus and...

Editor / Curator -
Citius, Biotech Stock Review
Biotech News

Citius (CTXR) Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal...

Editor / Curator -
steven boyd, biotech stock review
Biotech News

Armistice Capital Master Fund Ltd., and Citius Pharma (CTXR).

Editor / Curator -
candida auris, citius pharma, biotech stock review
Biotech News

Citius Pharma’s (CTXR) Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris.

Editor / Curator -

Latest article

Hagerty Garage and Social

Private Investor Meetup with Football Star Tim Wright.

All News Editor / Curator -
Saturday August 6th, Delray Beach Exclusive cocktail hour with Super Bowl Champion and Dome Audio Founder Tim Wright.

What is NAC (N-Acetyl-L-Cysteine)? (Dr Eric Berg)

Biotech News Editor / Curator -
https://youtu.be/oPdGOrqTfhA What is NAC good for? (and How Much to Take?)

FDA Issues Final ‘Enforcement Discretion’ Guidance on NAC.

Biotech News Editor / Curator -
NAC Crosses Major Hurdle With FDA. Is Bucillamine Next. Josh Long | Aug 01, 2022 "Industry, and...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: roland@institutionalanalyst.com
© Managed by Revelers.IO Media Group Inc.